The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI has launched an advisory board of oncology experts to provide guidance and strategic advice to the Chicago-based company on research, product development and clinical use of it's AI-enabled ...

Illumina & Tempus collaborate to drive future of precision medicine through genomic AI innovation: San Diego Saturday, April 19, 2025, 12:00 Hrs [IST] Illumina Inc. and Tempus AI, ...

Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms ...

BofA lowered the firm’s price target on Tempus AI (TEM) to $48 from $60 and keeps a Neutral rating on the shares. Sentiment for Life Sciences ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas ...

Illumina (ILMN) and Tempus AI (TEM) announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Norges Bank acquired a new position in Tempus AI, Inc. (NASDAQ:TEM – Free Report) in the 4th quarter, according to the ...

Tempus AI, a health tech firm, offers AI-powered platforms for treatment decisions, patient care, diagnostics, and molecular profiling, with growing revenue and improving margins. The "AI in ...